| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selenium NanoParticles| Category | Role in cancer | | -------------------------------- | ----------------------------------------------------------------------------------------------- | | Sodium Selenium (selenite) | Direct cytotoxic redox poison | | Selenium (organic / nutritional) | **Redox buffer & immune modulator** (generally *anti-therapy* when oxidative stress is desired) | | SeNPs | Tunable redox-signaling anticancer platform |The introduction of borneol led to a significant reduction in the size of selenium nanoparticles (SeNPs), as documented in the study (Prabhakaret et al., 2013). In the chemical synthesis of selenium nanoparticles, a precursor such as sodium selenite (Na₂SeO₃) is dissolved in water to form a homogenous solution. A reducing agent, like ascorbic acid or sodium borohydride (NaBH₄), is then added to the solution. The reducing agent donates electrons to the selenium ions (SeO32−SeO32), reducing them to elemental selenium (Se0Se^0). This reduction process leads to the nucleation of selenium atoms, which subsequently grow into nanoparticles through controlled aggregation. Se NPs might be hepatoprotective. (chemoprotective) (radioprotective) (radiosensitizer)
Selenium nanoparticles (SeNPs) are a biocompatible, less-toxic,
and more controllable form of selenium compared to inorganic salts (like sodium selenite).
Major SeNPs hepatoprotective mechanisms
Mechanism Description Key markers affected
1. Antioxidant activity SeNPs boost antioxidant enzyme ↓ ROS, ↓ MDA, ↑ GSH, ↑ GPx
systems (GPx, SOD, CAT) and scavenge
ROS directly.
2. Anti-inflammatory effect Downregulate NF-κB, TNF-α, ↓ TNF-α, ↓ IL-1β, ↓ IL-6
IL-6, and COX-2 pathways.
3. Anti-apoptotic action Balance between Bcl-2/Bax and reduce ↑ Bcl-2, ↓ Bax, ↓ Caspase-3
caspase-3 activation in hepatocytes.
4. Metal/toxin chelation SeNPs can bind or transform toxic ↓ liver metal accumulation
metals (Cd²⁺, Hg²⁺, As³⁺)
into less harmful complexes.
5. Mitochondrial protection Maintain membrane potential, Preserved ΔΨm, ↑ ATP
prevent mitochondrial ROS burst,
and ATP loss.
6. Regeneration support Stimulate hepatocyte proliferation ↑ PCNA, improved histology
and repair via redox signaling
and selenoproteins.
Comparison: SeNPs vs. Sodium Selenite
Property SeNPs Sodium Selenite
Toxicity Low Moderate–high
Bioavailability Controlled, often slow- Rapid, less controllable
release
ROS balance Adaptive, mild antioxidant Can flip to pro-oxidant easily
Safety margin Wide Narrow
Hepatoprotection Strong, sustained Protective at low dose,
toxic at high dose
Form of SeNPs matter:1. Core composition / capping agent: SeNPs can be stabilized with polysaccharides, proteins, or small molecules. Some stabilizers may interact with cellular redox systems differently—e.g., a protein-capped SeNP may have slower release and less ROS generation, whereas a bare SeNP might induce stronger ROS in cancer cells. 2. Particle size: Smaller SeNPs (<50 nm) tend to generate more ROS and may enhance anticancer activity, but could theoretically interfere with ROS-dependent chemo if administered simultaneously. Larger SeNPs are slower-acting and may be safer alongside chemo. 3. Surface charge / coating: Positively charged or functionalized SeNPs can preferentially enter tumor cells, whereas neutral or negatively charged forms may distribute more evenly. This affects both selective cytotoxicity and interaction with normal cells. "30 mg of Na2SeO3.5H2O was added to 90 mL of Milli-Q water. Ascorbic acid (10 mL, 56.7 mM) was added dropwise to sodium selenite solution with vigorous stirring. 10 µL of polysorbate were added after each 2 ml of ascorbic acid. Selenium nanoparticles were formed after the addition of ascorbic acid. This can be visualized by a color change of the reactant solution from clear white to clear red. All solutions were made in a sterile environment by using a sterile cabinet and double distilled water." SeNPs Cancer relevant pathways
Selenium Nanoparticles (SeNPs) and Alzheimer’s Disease (AD)Overview: Selenium nanoparticles (SeNPs) are being investigated in Alzheimer’s disease primarily as a multifunctional neuroprotective nanoplatform rather than as a conventional nutrient supplement. In AD-oriented studies, SeNPs are used for one or more of the following: (1) direct inhibition of amyloid-β (Aβ) aggregation, (2) reduction of oxidative stress, (3) lowering of neuroinflammation, (4) improved blood-brain barrier (BBB) transport via targeting ligands, and/or (5) delivery or stabilization of partner compounds with poor brain availability. Current support is mainly from cell studies and rodent AD models, so the evidence is still experimental/preclinical, not established clinical therapy.
Mechanistic Summary
Overall Modulation Direction in AD
Evidence LevelPreclinical. The AD literature for SeNPs is mainly cell culture and rodent-model work. Formulation-specific effects are important; benefits shown for one coated or ligand-targeted SeNP system should not automatically be generalized to all selenium nanoparticles or to ordinary selenium supplementation. Notes / Interpretation
SeNP-Associated Products / Components Used in AD-Oriented Nanoformulations
Bottom LineFor AD, selenium nanoparticles appear most relevant as a multi-target anti-amyloid / antioxidant nanocarrier platform. Their strongest support is for reducing Aβ aggregation and oxidative-neuroinflammatory injury while improving delivery of partner neuroprotective compounds. At present, this is a research-stage strategy, not a validated clinical AD treatment. |
| Source: CGL-CS |
| Type: |
| Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death). MAPK Pathways: The MAPK family includes several pathways, the most notable being: 1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival. 2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis. 3.p38 MAPK: Associated with inflammatory responses and apoptosis. Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations. Altered Expression Levels: Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival. Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling. The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers. Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion. |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:391 Target#:181 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid